In previous years, clinical trials of PDAC targeting angiogenesis such as vascular endothelial growth factor (VEGF) blocking basically failed, partly because VEGF antibody is believed to induce tumor growth by exacerbating hypoxia [177]. Here, VEGFA is linked to neoplasm.